Pampoentjies%D9%86%D9%83%D8%A7%D9%81%E0%A6%AE%E0%A6%BE%E0%A6%AE%E0%A7%8D%E0%A6%AA%E0%A7%8D%E2%80%8C%E0%A6%9BParotiditisQulaqdibi_x%C9%99st%C9%99liyi%D9%82%D9%88%D9%84%D8%A7%D9%82%D8%AF%DB%8C%D8%A8%DB%8C_%D8%AE%D8%B3%D8%AA%D9%87%E2%80%8C%D9%84%DB%8C%DA%AF%DB%8CBayoko%D0%A1%D1%8C%D0%B2%D1%96%D0%BD%D0%BA%D0%B0_(%D1%85%D0%B2%D0%B0%D1%80%D0%BE%D0%B1%D0%B0)%D0%AD%D0%BF%D1%96%D0%B4%D1%8D%D0%BC%D1%96%D1%87%D0%BD%D1%8B_%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D1%8B%D1%82%D0%95%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D1%87%D0%B5%D0%BD_%D0%BF%D0%B0%D1%80%D0%BE%D1%82%D0%B8%D1%82%E0%A6%AE%E0%A6%BE%E0%A6%AE%E0%A7%8D%E0%A6%AA%E0%A7%8D%E2%80%8C%E0%A6%B8Zau%C5%A1njaciParotiditis_epid%C3%A8mica%D9%85%D9%84%DB%95%D8%AE%DA%95%DB%95MumpsP%C5%99%C3%ADu%C5%A1niceClwy%27r_pennauF%C3%A5resygeMumpsPa%C5%8Be%C5%8B%DE%86%DE%AF%DE%8A%DE%AA%DE%87%DE%B0%DE%95%DE%A8%CE%A0%CE%B1%CF%81%CF%89%CF%84%CE%AF%CF%84%CE%B9%CE%B4%CE%B1MumpsMumpsParotiditisMumpsHazizurri%D8%A7%D9%88%D8%B1%DB%8C%D9%88%D9%86SikotautiOreillonsPlucamasA%27_PhloicParotidite_epid%C3%A9mica%D7%97%D7%96%D7%A8%D7%AA_(%D7%9E%D7%97%D7%9C%D7%94)%E0%A4%97%E0%A4%B2%E0%A4%B8%E0%A5%81%E0%A4%86Mumpsz%D4%B7%D5%BA%D5%AB%D5%A4%D5%A5%D5%B4%D5%AB%D5%AF_%D5%BA%D5%A1%D6%80%D6%85%D5%BF%D5%AB%D5%BFBegukOrelionoHettus%C3%B3tt
about
sameAs
Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of AgeImmunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and OlderSafety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of AgeSafety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the PhilippinesA Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese ChildrenImmunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifeMaking Decisions About the Measles-Mumps-Rubella VaccineComparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTMStudy of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersMeasles, Mumps, and Rubella (MMR) Immunity in College StudentsImmunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined VaccineSafety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy InfantsLong-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined VaccineStudy to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese InfantsImmunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesImmunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox DiseasesImmunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella VaccineSerological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose PresentationsImmunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ (2006-04-30)Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases (2005-11-30)Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
P1050
P279
P301
Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysisRemembering mumps.Mumps in the Vaccination Age: Global Epidemiology and the Situation in GermanyClinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
P921
Q61969984-F89F6928-3572-4B91-A514-E233968C4580Q63320360-06DF7135-AD74-4C74-803F-AD12CA19D240Q63840611-E180D70D-24C9-4453-8A2A-ED84767C0C7CQ64335917-7948D187-6E39-42BD-A610-DA238535F0AFQ64609801-1F63A9E9-DF99-462B-B95D-3382B804109DQ64636372-A4140FB8-45CE-4E58-8ECB-F2679BBBC9A3Q64638617-910A4543-D66D-4F70-966B-A2622144A4EBQ64642058-F3E3B35B-9FBB-40AD-AA63-A115BDDC14F4Q64649971-BFAAD09E-5517-4E78-B7C8-F80840A2A8B9Q64664172-F0A84729-7208-4E8B-BD23-F6116C910421Q64678488-88290058-6F9B-4BEF-85DF-D74B45AD870AQ64695474-C47A9B3B-F0AB-4749-AEB1-B816B320DF0AQ64716610-0E58B448-5BC5-405B-AC1F-6589068C25F0Q65387500-E0DD1A4B-82B9-4893-87A7-9DF3D880B98CQ65391390-AC5B0217-E6AB-46F5-9EBE-946196BD7FC8Q65394408-A2F4CC3B-1AC4-4015-BB1B-B5CAF2C93715Q65473330-A2619B98-9DC4-4E8D-9806-BB8E320D4A78Q66032252-C4CCDB65-13EB-4AC7-89A7-1241DAFCE476Q66032262-C5DE278C-EB60-454D-9FE1-F0BAC0427B8BQ66044077-C77629BC-BFF9-4549-BC27-59380DC57E8BQ66059097-4FD462A7-50B3-40D2-941A-C0C116E16946Q66059099-B440F67E-A239-4D4E-BB39-8F0DD1B114A4Q66082452-1D6C5AA6-4997-457E-8BA3-46E6E44AD6C9Q66344537-143CB415-EDA0-4893-B4F5-DAC7938ED48FQ66345634-F591C157-7672-4A5D-A0D0-A49260DD277FQ86245136-2C4D005F-4858-48EA-9B8C-10E5A1B7E34FQ86249311-DE45EB7E-CCFA-4B3D-B572-51925F75E5E8Q92392103-0DFCBAC1-252D-4F32-A396-1F76EFE4D389
P1050
description
Human disease caused by paramyxovirus
@en
Infektim viral ngjites
@sq
ansteckende Virusinfektion
@de
choroba wirusowa
@pl
doenza contaxiosa
@gl
doença humana viral e contagiosa
@pt
enfermedad contagiosa
@es
homa virusa malsano
@eo
infekční onemocnění
@cs
kinderziekte
@nl
name
A' Phloic
@gd
Bayoko
@bcl
Beguk
@id
Beguk
@ms
Beke
@tl
Boufletes
@wa
Buffits
@sco
Clwy'r pennau
@cy
Gondhong
@jv
Hapgyrtma
@tk
type
label
A' Phloic
@gd
Bayoko
@bcl
Beguk
@id
Beguk
@ms
Beke
@tl
Boufletes
@wa
Buffits
@sco
Clwy'r pennau
@cy
Gondhong
@jv
Hapgyrtma
@tk
altLabel
Bệnh chàm chàm
@vi
Bệnh quai bị
@vi
Cachumba
@pt
Caxumba
@pt
Clwy pennau
@cy
Doença Caxumba
@pt
Epideemiline kõrva-süljenäärmepõletik
@et
Epideemiline parotiit
@et
Epidemik parotit
@tr
Epidemični parotitis
@sl
prefLabel
A' Phloic
@gd
Bayoko
@bcl
Beguk
@id
Beguk
@ms
Beke
@tl
Boufletes
@wa
Buffits
@sco
Clwy'r pennau
@cy
Gondhong
@jv
Hapgyrtma
@tk